Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price gapped up prior to trading on Wednesday after Truist Financial raised their price target on the stock from $32.00 to $38.00. The stock had previously closed at $24.59, but opened at $28.00. Truist Financial currently has a buy rating on the stock. Agios Pharmaceuticals shares last traded at $28.6680, with a volume of 2,098,761 shares trading hands.

Several other brokerages have also recently weighed in on AGIO. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday. Citigroup initiated coverage on Agios Pharmaceuticals in a report on Wednesday, November 26th. They issued a “buy” rating and a $38.00 target price on the stock. Bank of America raised their price target on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank Of Canada downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $57.00 to $28.00 in a research report on Wednesday, November 19th. Finally, The Goldman Sachs Group decreased their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.22.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the transaction, the insider owned 61,727 shares in the company, valued at $2,711,049.84. The trade was a 5.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 3,902 shares of company stock valued at $170,754. Insiders own 4.30% of the company’s stock.

Key Stores Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA approval: AQVESME (mitapivat) received FDA approval for anemia in adults with alpha‑ and beta‑thalassemia — making mitapivat the only approved oral therapy for these thalassemia types and opening a new commercial market for Agios. Business Insider: FDA Approves AQVESME
• Positive Sentiment: Regulatory detail & safety program: Approval includes a REMS/labeling requirement but confirms the indication expansion that investors had been anticipating, increasing near‑term revenue visibility. Zacks: Mitapivat Gets FDA Nod with REMS
• Positive Sentiment: Analyst upgrades/price target increases: Bank of America bumped its target to $34 (buy) and Truist raised its target to $38 and reiterated a buy — analysts cite the new indication as a revenue catalyst. Yahoo Finance: Price Target Raised
• Positive Sentiment: Commercial pricing and market expectation: Reports indicate list/pricing intentions near ~$425k per patient per year, which, combined with the exclusive oral label, supports material revenue potential if uptake and reimbursement follow. MSN: Pricing Report
• Neutral Sentiment: Media & transcript coverage: Multiple writeups, press releases and an investor/transcript slide deck circulated summarizing the approval and commercial plan — useful context for investors but incremental to the headline approval. Seeking Alpha: Approval Transcript
• Neutral Sentiment: Trading action: Shares were temporarily halted for a news release ahead of the announcement and volume spiked as the approval and analyst reactions hit the tape — heightened liquidity can amplify intraday moves.
• Negative Sentiment: Safety/label limitation: The approval includes a boxed warning/REMS for potential liver injury — this safety profile may temper prescribing, restrict use, and complicate commercial uptake. Seeking Alpha: Analysis and Risks
• Negative Sentiment: Revenue ceiling and payer risk: Several analysts/notes flag that thalassemia peak sales estimates (~$500M) may not be enough by itself to drive profitability; high list price could trigger payer restrictions or access delays. Seeking Alpha: Commercial Outlook
• Neutral Sentiment: Short interest note: Recent short‑interest data in the feed is anomalous/zero and likely not informative; monitor later filings for accurate short positioning.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AGIO. Invesco Ltd. grew its holdings in shares of Agios Pharmaceuticals by 28.6% during the first quarter. Invesco Ltd. now owns 107,367 shares of the biopharmaceutical company’s stock valued at $3,146,000 after buying an additional 23,852 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Agios Pharmaceuticals by 207.6% in the 1st quarter. Russell Investments Group Ltd. now owns 8,558 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 5,776 shares in the last quarter. American Century Companies Inc. lifted its position in Agios Pharmaceuticals by 9.6% in the 1st quarter. American Century Companies Inc. now owns 114,947 shares of the biopharmaceutical company’s stock valued at $3,368,000 after acquiring an additional 10,110 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in Agios Pharmaceuticals by 33.2% during the 1st quarter. Rafferty Asset Management LLC now owns 93,627 shares of the biopharmaceutical company’s stock valued at $2,743,000 after purchasing an additional 23,314 shares during the last quarter. Finally, Kodai Capital Management LP bought a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $1,485,000.

Agios Pharmaceuticals Trading Up 17.5%

The stock has a market capitalization of $1.69 billion, a P/E ratio of -4.13 and a beta of 0.87. The business has a fifty day simple moving average of $34.03 and a 200 day simple moving average of $36.26.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. During the same quarter in the previous year, the firm earned $16.22 earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.